A citation-based method for searching scientific literature

Emmanuel S Antonarakis, Farah Shaukat, Pedro Isaacsson Velho, Harsimar Kaur, Eugene Shenderov, Drew M Pardoll, Tamara L Lotan. Eur Urol 2019
Times Cited: 91







List of co-cited articles
1039 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade.
Wassim Abida, Michael L Cheng, Joshua Armenia, Sumit Middha, Karen A Autio, Hebert Alberto Vargas, Dana Rathkopf, Michael J Morris, Daniel C Danila, Susan F Slovin,[...]. JAMA Oncol 2019
259
52

Integrative clinical genomics of advanced prostate cancer.
Dan Robinson, Eliezer M Van Allen, Yi-Mi Wu, Nikolaus Schultz, Robert J Lonigro, Juan-Miguel Mosquera, Bruce Montgomery, Mary-Ellen Taplin, Colin C Pritchard, Gerhardt Attard,[...]. Cell 2015
48

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
Dung T Le, Jennifer N Durham, Kellie N Smith, Hao Wang, Bjarne R Bartlett, Laveet K Aulakh, Steve Lu, Holly Kemberling, Cara Wilt, Brandon S Luber,[...]. Science 2017
45

Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.
Colin C Pritchard, Joaquin Mateo, Michael F Walsh, Navonil De Sarkar, Wassim Abida, Himisha Beltran, Andrea Garofalo, Roman Gulati, Suzanne Carreira, Rosalind Eeles,[...]. N Engl J Med 2016
790
40

Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer.
Yi-Mi Wu, Marcin Cieślik, Robert J Lonigro, Pankaj Vats, Melissa A Reimers, Xuhong Cao, Yu Ning, Lisha Wang, Lakshmi P Kunju, Navonil de Sarkar,[...]. Cell 2018
260
37

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
Joaquin Mateo, Suzanne Carreira, Shahneen Sandhu, Susana Miranda, Helen Mossop, Raquel Perez-Lopez, Daniel Nava Rodrigues, Dan Robinson, Aurelius Omlin, Nina Tunariu,[...]. N Engl J Med 2015
36


MSH2 Loss in Primary Prostate Cancer.
Liana B Guedes, Emmanuel S Antonarakis, Michael T Schweizer, Nooshin Mirkheshti, Fawaz Almutairi, Jong Chul Park, Stephanie Glavaris, Jessica Hicks, Mario A Eisenberger, Angelo M De Marzo,[...]. Clin Cancer Res 2017
87
29

Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer.
Tomasz M Beer, Eugene D Kwon, Charles G Drake, Karim Fizazi, Christopher Logothetis, Gwenaelle Gravis, Vinod Ganju, Jonathan Polikoff, Fred Saad, Piotr Humanski,[...]. J Clin Oncol 2017
396
28

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.
Eugene D Kwon, Charles G Drake, Howard I Scher, Karim Fizazi, Alberto Bossi, Alfons J M van den Eertwegh, Michael Krainer, Nadine Houede, Ricardo Santos, Hakim Mahammedi,[...]. Lancet Oncol 2014
930
28

Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study.
Emmanuel S Antonarakis, Josep M Piulats, Marine Gross-Goupil, Jeffrey Goh, Kristiina Ojamaa, Christopher J Hoimes, Ulka Vaishampayan, Ranaan Berger, Ahmet Sezer, Tuomo Alanko,[...]. J Clin Oncol 2020
229
28

Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer.
Colin C Pritchard, Colm Morrissey, Akash Kumar, Xiaotun Zhang, Christina Smith, Ilsa Coleman, Stephen J Salipante, Jennifer Milbank, Ming Yu, William M Grady,[...]. Nat Commun 2014
173
27

Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.
Daniel Nava Rodrigues, Pasquale Rescigno, David Liu, Wei Yuan, Suzanne Carreira, Maryou B Lambros, George Seed, Joaquin Mateo, Ruth Riisnaes, Stephanie Mullane,[...]. J Clin Invest 2018
90
25

Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study.
A R Hansen, C Massard, P A Ott, N B Haas, J S Lopez, S Ejadi, J M Wallmark, B Keam, J-P Delord, R Aggarwal,[...]. Ann Oncol 2018
172
24

Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.
Elena Castro, Chee Goh, David Olmos, Ed Saunders, Daniel Leongamornlert, Malgorzata Tymrakiewicz, Nadiya Mahmud, Tokhir Dadaev, Koveela Govindasami, Michelle Guy,[...]. J Clin Oncol 2013
423
23

Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death.
Rong Na, S Lilly Zheng, Misop Han, Hongjie Yu, Deke Jiang, Sameep Shah, Charles M Ewing, Liti Zhang, Kristian Novakovic, Jacqueline Petkewicz,[...]. Eur Urol 2017
183
23

Olaparib for Metastatic Castration-Resistant Prostate Cancer.
Johann de Bono, Joaquin Mateo, Karim Fizazi, Fred Saad, Neal Shore, Shahneen Sandhu, Kim N Chi, Oliver Sartor, Neeraj Agarwal, David Olmos,[...]. N Engl J Med 2020
564
23

Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.
Emmanuel S Antonarakis, Changxue Lu, Brandon Luber, Chao Liang, Hao Wang, Yan Chen, John L Silberstein, Danilo Piana, Zhao Lai, Yidong Chen,[...]. Eur Urol 2018
105
21

Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer.
Julie N Graff, Joshi J Alumkal, Charles G Drake, George V Thomas, William L Redmond, Mohammad Farhad, Jeremy P Cetnar, Frederick S Ey, Raymond C Bergan, Rachel Slottke,[...]. Oncotarget 2016
236
19

Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer.
Pedro Isaacsson Velho, John L Silberstein, Mark C Markowski, Jun Luo, Tamara L Lotan, William B Isaacs, Emmanuel S Antonarakis. Prostate 2018
61
29

The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer.
Mark M Pomerantz, Sandor Spisák, Li Jia, Angel M Cronin, Istvan Csabai, Elisa Ledet, A Oliver Sartor, Irene Rainville, Edward P O'Connor, Zachary T Herbert,[...]. Cancer 2017
147
19

Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer.
Karim Boudadi, Daniel L Suzman, Valsamo Anagnostou, Wei Fu, Brandon Luber, Hao Wang, Noushin Niknafs, James R White, John L Silberstein, Rana Sullivan,[...]. Oncotarget 2018
96
18

Integrative Clinical Genomics of Advanced Prostate Cancer.
Dan Robinson, Eliezer M Van Allen, Yi-Mi Wu, Nikolaus Schultz, Robert J Lonigro, Juan-Miguel Mosquera, Bruce Montgomery, Mary-Ellen Taplin, Colin C Pritchard, Gerhardt Attard,[...]. Cell 2015
291
17

Cyclin-Dependent Kinase 12, Immunity, and Prostate Cancer.
Emmanuel S Antonarakis. N Engl J Med 2018
42
38

The long tail of oncogenic drivers in prostate cancer.
Joshua Armenia, Stephanie A M Wankowicz, David Liu, Jianjiong Gao, Ritika Kundra, Ed Reznik, Walid K Chatila, Debyani Chakravarty, G Celine Han, Ilsa Coleman,[...]. Nat Genet 2018
380
17

Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer.
Elena Castro, Chee Goh, Daniel Leongamornlert, Ed Saunders, Malgorzata Tymrakiewicz, Tokhir Dadaev, Koveela Govindasami, Michelle Guy, Steve Ellis, Debra Frost,[...]. Eur Urol 2015
187
17

Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer.
Matti Annala, Werner J Struss, Evan W Warner, Kevin Beja, Gillian Vandekerkhove, Amanda Wong, Daniel Khalaf, Irma-Liisa Seppälä, Alan So, Gregory Lo,[...]. Eur Urol 2017
131
17

Genomic correlates of clinical outcome in advanced prostate cancer.
Wassim Abida, Joanna Cyrta, Glenn Heller, Davide Prandi, Joshua Armenia, Ilsa Coleman, Marcin Cieslik, Matteo Benelli, Dan Robinson, Eliezer M Van Allen,[...]. Proc Natl Acad Sci U S A 2019
398
17

CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors.
Emmanuel S Antonarakis, Pedro Isaacsson Velho, Wei Fu, Hao Wang, Neeraj Agarwal, Victor Sacristan Santos, Benjamin L Maughan, Roberto Pili, Nabil Adra, Cora N Sternberg,[...]. JCO Precis Oncol 2020
73
21

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.
Dung T Le, Jennifer N Uram, Hao Wang, Bjarne R Bartlett, Holly Kemberling, Aleksandra D Eyring, Andrew D Skora, Brandon S Luber, Nilofer S Azad, Dan Laheru,[...]. N Engl J Med 2015
16

PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer.
Elena Castro, Nuria Romero-Laorden, Angela Del Pozo, Rebeca Lozano, Ana Medina, Javier Puente, Josep Maria Piulats, David Lorente, Maria Isabel Saez, Rafael Morales-Barrera,[...]. J Clin Oncol 2019
145
16

Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines.
Piper Nicolosi, Elisa Ledet, Shan Yang, Scott Michalski, Brandy Freschi, Erin O'Leary, Edward D Esplin, Robert L Nussbaum, Oliver Sartor. JAMA Oncol 2019
122
16

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
Christopher J Sweeney, Yu-Hui Chen, Michael Carducci, Glenn Liu, David F Jarrard, Mario Eisenberger, Yu-Ning Wong, Noah Hahn, Manish Kohli, Matthew M Cooney,[...]. N Engl J Med 2015
15

Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
Philip W Kantoff, Celestia S Higano, Neal D Shore, E Roy Berger, Eric J Small, David F Penson, Charles H Redfern, Anna C Ferrari, Robert Dreicer, Robert B Sims,[...]. N Engl J Med 2010
15

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Suzanne L Topalian, F Stephen Hodi, Julie R Brahmer, Scott N Gettinger, David C Smith, David F McDermott, John D Powderly, Richard D Carvajal, Jeffrey A Sosman, Michael B Atkins,[...]. N Engl J Med 2012
15

Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study.
Wassim Abida, David Campbell, Akash Patnaik, Jeremy D Shapiro, Brieuc Sautois, Nicholas J Vogelzang, Eric G Voog, Alan H Bryce, Ray McDermott, Francesco Ricci,[...]. Clin Cancer Res 2020
144
15

Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.
Karim Fizazi, NamPhuong Tran, Luis Fein, Nobuaki Matsubara, Alfredo Rodriguez-Antolin, Boris Y Alekseev, Mustafa Özgüroğlu, Dingwei Ye, Susan Feyerabend, Andrew Protheroe,[...]. N Engl J Med 2017
14

The mutational landscape of lethal castration-resistant prostate cancer.
Catherine S Grasso, Yi-Mi Wu, Dan R Robinson, Xuhong Cao, Saravana M Dhanasekaran, Amjad P Khan, Michael J Quist, Xiaojun Jing, Robert J Lonigro, J Chad Brenner,[...]. Nature 2012
14

Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer.
Heather H Cheng, Colin C Pritchard, Thomas Boyd, Peter S Nelson, Bruce Montgomery. Eur Urol 2016
182
14

Increased survival with enzalutamide in prostate cancer after chemotherapy.
Howard I Scher, Karim Fizazi, Fred Saad, Mary-Ellen Taplin, Cora N Sternberg, Kurt Miller, Ronald de Wit, Peter Mulders, Kim N Chi, Neal D Shore,[...]. N Engl J Med 2012
14

Clinical implications of PTEN loss in prostate cancer.
Tamara Jamaspishvili, David M Berman, Ashley E Ross, Howard I Scher, Angelo M De Marzo, Jeremy A Squire, Tamara L Lotan. Nat Rev Urol 2018
232
14

Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making.
Wassim Abida, Joshua Armenia, Anuradha Gopalan, Ryan Brennan, Michael Walsh, David Barron, Daniel Danila, Dana Rathkopf, Michael Morris, Susan Slovin,[...]. JCO Precis Oncol 2017
200
13

Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.
Joaquin Mateo, Nuria Porta, Diletta Bianchini, Ursula McGovern, Tony Elliott, Robert Jones, Isabel Syndikus, Christy Ralph, Suneil Jain, Mohini Varughese,[...]. Lancet Oncol 2020
247
13

Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.
David A Quigley, Ha X Dang, Shuang G Zhao, Paul Lloyd, Rahul Aggarwal, Joshi J Alumkal, Adam Foye, Vishal Kothari, Marc D Perry, Adina M Bailey,[...]. Cell 2018
245
12

Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories.
Renea A Taylor, Michael Fraser, Julie Livingstone, Shadrielle Melijah G Espiritu, Heather Thorne, Vincent Huang, Winnie Lo, Yu-Jia Shiah, Takafumi N Yamaguchi, Ania Sliwinski,[...]. Nat Commun 2017
129
12

Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate.
Michael T Schweizer, Heather H Cheng, Maria S Tretiakova, Funda Vakar-Lopez, Nola Klemfuss, Eric Q Konnick, Elahe A Mostaghel, Peter S Nelson, Evan Y Yu, Bruce Montgomery,[...]. Oncotarget 2016
53
20

Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis.
Gail P Risbridger, Renea A Taylor, David Clouston, Ania Sliwinski, Heather Thorne, Sally Hunter, Jason Li, Gillian Mitchell, Declan Murphy, Mark Frydenberg,[...]. Eur Urol 2015
77
14

Abiraterone and increased survival in metastatic prostate cancer.
Johann S de Bono, Christopher J Logothetis, Arturo Molina, Karim Fizazi, Scott North, Luis Chu, Kim N Chi, Robert J Jones, Oscar B Goodman, Fred Saad,[...]. N Engl J Med 2011
12

Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer.
Himisha Beltran, Davide Prandi, Juan Miguel Mosquera, Matteo Benelli, Loredana Puca, Joanna Cyrta, Clarisse Marotz, Eugenia Giannopoulou, Balabhadrapatruni V S K Chakravarthi, Sooryanarayana Varambally,[...]. Nat Med 2016
774
12

Tumor Mutational Burden and Response Rate to PD-1 Inhibition.
Mark Yarchoan, Alexander Hopkins, Elizabeth M Jaffee. N Engl J Med 2017
12


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.